Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia

Journal of Clinical Psychiatry

Volumn 68, Issue 1, 2007, Pages 75-80

  Karow, Anne ^a   Czekalla, Joerg ^b   Dittmann, Ralf W ^b   Schacht, Alexander ^b   Wagner, Thomas ^b   Lambert, Martin ^a   Schimmelmann, Benno G ^c   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FACTORIAL ANALYSIS; FEMALE; GERMANY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WELLBEING;

EID: 33846881775     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0110     Document Type: Article

References (48)

1. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 2005;427:43-46
2. Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and non-psychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003;65:156-162
3. Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508-516
4. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
5. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64:1308-1315
6. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
7. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(suppl 16):10-13
8. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
9. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996;312:345-349
10. O'Donnell C, Donohoe G, Sharkey L, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003;327:834
11. Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005;111:106-115
12. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl 2005;427:29-34
13. Awad AG, Voruganti LN. Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand Suppl 2005;427:6-13
14. Naber D, Lambert M, Karow A. Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease. Psychiatr Prax 2004;31(suppl 2):S230-S232
15. Awad AG, Naber D. Neuroleptic dysphoria 50 years later. Acta Psychiatr Scand Suppl 2005;427:5
16. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002;16:457-471
17. DeHaan L. Patient's Perspectives: Subjective Experiences and Attitudes of Patients With Recent Onset Schizophrenia [thesis]. Amsterdam, the Netherlands: University of Amsterdam; 2002
18. Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatr Scand 2005;111:81-83
19. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3-10
20. Bobes J. Current status of quality of life assessment in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 2001;251(suppl 2):38-42
21. Sim K, Mahendran R, Siris SG, et al. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 2004;129:141-147
22. Wetherell JL, Palmer BW, Thorp SR, et al. Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2003;64:1476-1482
23. Huppert JD, Weiss KA, Lim R, et al. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001;51:171-180
24. Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 2001;189:669-675
25. Karow A, Moritz S, Lambert M, et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005;38:320-326
26. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65:932-939
27. Silva DL, de Jesus MJ, Breier A, et al. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 2005;66:831-838
28. Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66:331-338
29. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005;15:249-258
30. Lambert M, Schimmelmann BG, Karow A, et al. Subjective well-being and initial dysphoric reaction under antipsychotic drugs: concepts, measurement and clinical relevance. Pharmacopsychiatry 2003;36 (suppl 3):S181-S190
31. Voruganti LP, Awad AG. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects? Can J Psychiatry 2004;49:285-289
32. Voruganti LP, Awad AG. Brain imaging research on subjective responses to psychotropic drugs. Acta Psychiatr Scand Suppl 2005;427:22-28
33. Carrick R, Mitchell A, Powell RA, et al. The quest for well-being: a qualitative study of the experience of taking antipsychotic medication. Psychol Psychother 2004;77:19-33
34. Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220-231
35. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(suppl 3):133-138
36. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88
37. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-446
38. DeHaan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002;162:24-28
39. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003;416:16-23
40. Lambert M, Haro JM, Novick D, et al. Olanzapine vs other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005;111:232-243
41. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006;67:1690-1697
42. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
43. Velligan DI, Lam F, Ereshefsky L, et al. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-667
44. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
45. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with ' schizophrenia. Psychiatry Res 2005;133:129-133
46. Czekalla J, Linder P, Wagner T, et al. Improvement of suicidal ideation and medication acceptance under treatment with orally disintegrating and coated olanzapine tablets: results from a prospective multi-center study of acutely ill psychiatric inpatients. Schizophr Res 2004;67(suppl 1):214
47. Wehmeier PM, Schneider E, Siemer A, et al. Correlation of QLS and SWN scores depends on the time on treatment in patients with schizophrenia. Schizophr Res 2006;81(suppl 1):298
48. Czekalla J, Siemer A, Wagner T, et al. Benzodiazepine co-medication of acutely aggressive psychiatric inpatients treated with olanzapine and other antipsychotics. Schizophr Res 2006;81(suppl 1):78